Overview

A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes

Status:
Not yet recruiting
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated